Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.58 |
| ▸ | DRD2 | P14416 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809552 | 0.90 | ADRA1A (0.59) | DRD3DRD2ADRA1AHTR1ADRD4 | |
| SCHEMBL13809557 | 0.90 | ADRA1A (0.64) | DRD3DRD2ALDH1A1SMN1; SMN2ADRA1A | |
| SCHEMBL13809547 | 0.87 | DRD3 (0.59) | DRD3DRD2ADRA1AHTR1ADRD4 | |
| SCHEMBL13809560 | 0.87 | ADRA1A (0.55) | DRD3DRD2ADRA1ATSHRHTR1A | |
| SCHEMBL13809543 | 0.85 | DRD3 (0.60) | DRD3DRD2ADRA1ADRD4 | |
| SCHEMBL13809551 | 0.84 | ADRA1A (0.68) | DRD3DRD2ADRA1AHTR1ADRD4 | |
| SCHEMBL4301030 | 0.83 | ADRA1A (0.54) | DRD3DRD2ADRA1AHTR1ADRD4 | |
| SCHEMBL13809540 | 0.82 | ADRA1A (0.53) | DRD3DRD2ADRA1AHTR1ADRD4 | |
| SCHEMBL13809556 | 0.81 | ADRA1A (0.53) | DRD3DRD2ADRA1A | |
| SCHEMBL13809564 | 0.81 | ADRA1A (0.57) | DRD3DRD2ALDH1A1ADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | DRD3 1/4885DRD2 2/4885ALDH1A1 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.